BCMA Drug Prices For Multiple Myeloma Don't Match Their Benefit, ICER Concludes
BMS And J&J CAR-Ts, And GSK's ADC Were Reviewed By ICER
Executive Summary
Despite the net health benefits of Abecma, the price is too high, while Blenrep has low long-term value for the cost, according to ICER's benchmarks.